ashish kumarGlobal Breast Cancer Liquid Biopsy Market Statistics: USD 497.2 Million Value by 2032
Summary:
- The global breast cancer liquid biopsy market size reached USD 130.4 Million in 2023.
- The market is expected to reach USD 497.2 Million Billion by 2032, exhibiting a growth rate (CAGR) of 15.5% during 2024-2032.
- North America leads the market, accounting for the largest breast cancer liquid biopsy market share.
- Reagent kits account for the majority of the market share in the product services segment due to their frequent use across various stages of the liquid biopsy process.
- Based on the circulating biomarkers, the market has been classified into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and others.
- On the basis of the end user, the market has been divided into reference laboratories, hospitals and physician laboratories, and others.
- The increasing preference for non-invasive diagnostic solutions is a primary driver of the breast cancer liquid biopsy market.
- Technological advancements in molecular biology and genetic sequencing, coupled with the rising trend of personalized medicine, are reshaping the breast cancer liquid biopsy market.
Breast Cancer Liquid Biopsy Industry Trends and Drivers:
- Rising demand for non-invasive diagnostic methods:
The increasing number of patients and healthcare providers that are opting for non-invasive diagnostic solutions over traditional surgical biopsies represents one of the key factors contributing to the growth of the market. Liquid biopsy, which involves analyzing a small blood sample, is becoming a preferred choice because it offers a less painful, faster, and safer alternative. The convenience and reduced recovery time associated with this method are driving the demand in clinics and hospitals for such treatment. In addition, the ability to detect cancer at earlier stages through circulating tumor DNA (ctDNA) analysis is improving patient outcomes. As healthcare facilities are looking to enhance diagnostic accuracy while minimizing patient discomfort, the adoption of liquid biopsy is rising.
- Technological advancements in biomarker detection:
Biotechnology companies and research institutions are focusing on developing more sophisticated methods for detecting breast cancer-specific biomarkers in blood samples. Recent advancements in molecular biology and genetic sequencing are allowing for the detection of cancer at much earlier stages, often before symptoms appear. These technologies are making it easier for clinicians to monitor cancer recurrence and treatment response over time. Innovations, such as next-generation sequencing (NGS) and digital polymerase chain reaction (PCR), are enabling higher sensitivity and specificity in biomarker detection, thereby improving diagnostic accuracy. The increasing investments in refining these technologies to improve accuracy and reliability of liquid biopsy are propelling the market growth.
- Growing focus on personalized medicine:
The rising emphasis on personalized medicine in oncology, with liquid biopsy playing a significant role in its implementation is bolstering the market growth. Physicians are using genetic and molecular information gathered from blood samples to customize treatment plans based on the unique cancer profile of each patient. This approach is helping to identify the most effective therapies for individuals, which is minimizing adverse reactions and improving survival rates. Furthermore, liquid biopsy allows for real-time monitoring of how the cancer is responding to treatment, enabling more timely adjustments. As the shift towards precision medicine is increasing, the integration of liquid biopsy into routine breast cancer care is offering a favorable market outlook.
Request for a sample copy of this report: https://www.imarcgroup.com/breast-cancer-liquid-biopsy-market/requestsample
Breast Cancer Liquid Biopsy Market Report Segmentation:
Breakup By Product Services:
- Reagent Kits
- Instruments
- Services
Reagent kits represent the largest segment as they provide the necessary tools and materials for detecting and analyzing cancer biomarkers.
Breakup By Circulating Biomarker:
- Circulating Tumor Cells (CTCs)
- Cell-Free DNA (cfDNA)
- Extracellular Vesicles (EVs)
- Others
Based on the circulating biomarkers, the market has been classified into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and others.
Breakup By End User:
- Reference Laboratories
- Hospitals and Physician Laboratories
- Others
On the basis of the end user, the market has been divided into reference laboratories, hospitals and physician laboratories, and others.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position in the breast cancer liquid biopsy market due to its advanced healthcare infrastructure, high adoption of cutting-edge technologies, and increasing investments in research and development (R&D) activities for cancer.
Top Breast Cancer Liquid Biopsy Market Leaders: The breast cancer liquid biopsy market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:
- Biocept Inc.
- Bio-Rad Laboratories Inc.
- F. Hoffmann-La Roche AG
- Fluxion Biosciences Inc.
- Guardant Health Inc.
- Illumina Inc.
- Menarini Silicon Biosystems (The Menarini Group)
- NeoGenomics Laboratories Inc.
- Qiagen and Sysmex Europe SE (Sysmex Corporation).
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
